Form 4: Vaxcyte SVP Mikhail Eydelman Reports Stock Transactions

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., reports the acquisition and disposal of common stock and derivative securities.

Summary

• On June 3, 2024, Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., engaged in transactions involving the company's common stock.
• Eydelman acquired 1,667 shares of common stock at $21.41 per share through the exercise of stock options.
• He also sold 751 shares at a weighted average price of $71.251, 656 shares at a weighted average price of $72.366, and 260 shares at a weighted average price of $73.637.
• These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 29, 2023.
• Following these transactions, Eydelman directly owns 31,161 shares of common stock and 184,998 stock options.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are part of a pre-planned trading strategy, and the executive still holds a significant number of shares and options.

Positives

• The exercise of stock options demonstrates Eydelman's belief in the company's future prospects.

Negatives

• The sale of shares, even under a pre-arranged plan, could be interpreted as a lack of confidence, although Rule 10b5-1 plans are often used for diversification or tax planning.

Risks

• Executive stock sales can sometimes create negative market sentiment, regardless of the underlying reason for the sale.

Industry Context

Insider transactions are common and closely monitored in the pharmaceutical industry, as they can provide insights into management's perspective on the company's prospects. Rule 10b5-1 plans are frequently used to avoid accusations of insider trading.

Comparison to Industry Standards

• Comparing Eydelman's transactions to those of executives at similar biotech companies like Moderna (MRNA) or BioNTech (BNTX) would provide context.
• For example, if executives at those companies are also selling shares under 10b5-1 plans, it could indicate a broader trend of diversification or profit-taking in the industry.
• Analyzing the size and frequency of these transactions relative to Eydelman's total holdings and the company's market capitalization is also important.
• A large sale might raise more concerns than a smaller, routine transaction.

Stakeholder Impact

• The transactions could have a minor impact on shareholder sentiment, depending on how they are perceived by the market.

Key Dates